The performance of two AI chatbots in the ophthalmology board examination.
Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial
Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large